Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from AbbVie Inc.

Expert Illustrations & Commentaries™: Advances in Therapies for Patients with Migraine—A Changing Therapeutic Landscape

Release Date: July 30, 2021
Expiration Date: July 30, 2022

Activity Overview

Expert Illustrations and Commentaries™ is a video-based program in which two experts discuss the etiology and management of various illnesses. In the current activity the faculty focus on the pathophysiology of migraine and therapeutic strategies for its management, both current and emerging. The discussion is enriched by video animation that illustrates migraine pathophysiology and the mechanisms of action of some of the newer CGRP-targeted therapies. These segments help to make a somewhat complicated subject easier to understand. The format is designed to help clinicians identify best practices in the diagnosis and management of migraine and improve outcomes for patients with the disease.

Migraine is a disabling neurological disorder and a major public health problem, affecting approximately 39 million individuals in the United States. However, only 3% to 13% of patients with migraine are on preventive therapy. Treatment of individual migraine episodes is important to prevent the progression to chronic migraine. Treatments for the prevention of episodic and chronic migraine are currently available, with new and emerging therapies on the horizon that will provide new options for safe and effective targeted treatment. In addition, lifestyle modifications and other strategies have been recommended to minimize the burden of migraine. Learn from this discussion between Jessica Ailani, MD, and Anna Pace, MD, headache experts who treat many patients with migraine.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AbbVie Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward primary care physicians and neurologists as well as NPs and PAs. Other clinicians involved in the care of patients suffering from migraine are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess the clinical features of migraine that impact quality of life
  • Select appropriate treatments for patients with acute migraine based on benefits and risks of therapy
  • Examine current and emerging treatment options for migraine prevention based on efficacy and safety data
  • Develop treatment plans for patients with migraine based on patient preferences and shared goals of therapy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Jessica Ailani, MD
Jessica Ailani, MD
Director Medstar Georgetown Headache Center
Vice Co-Chair Strategic Planning Neurology
Professor Clinical Neurology
Department of Neurology
Medstar Georgetown University Hospital
Washington, DC

Disclosures: Grant/Research Support: AbbVie Inc.; Eli Lilly; Zosano Pharma Corporation; Satsuma Pharmaceuticals, Inc.; Biohaven Pharmaceuticals, Inc.; Consultant: AbbVie Inc.; Aeon Biopharma, Inc.; Amgen Inc.; Biohaven Pharmaceuticals, Inc.; Eli Lilly; Glaxosmithkline, Nēsos Corp; Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Biohaven Pharmaceuticals, Inc.; Eli Lilly; Lundbeck; Teva Pharmaceutical Industries Ltd.; Theranica Bio-Electronics Ltd.; Impel NeuroPharma, Inc.; Lundbeck; Stock/Shareholder: Ctrl M Health.

Anna Pace, MD
Anna Pace, MD
Assistant Professor
Division of Headache Medicine
Department of Neurology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Dr. Anna Pace, MD has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By